Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis

Journal of Clinical Pharmacology

Volumn 51, Issue 1, 2011, Pages 93-101

  Korth Bradley, Joan M ^a   Baird Bellaire, Susan J ^a   Patat, Alain A ^b   Troy, Steven M ^c   Böhmer, Gabriele M ^d   Gleiter, Christoph H ^d   Buecheler, Reinhild ^d   Morgan, Marsha Y ^e  

^a PFIZER INC   (United States)

^b Biotrial   (France)

^c SHIRE   (United States)

^d University Hospital of Tuebingen   (Germany)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Glycylcycline; hepatic impairment; tigecycline

Indexed keywords

TIGECYCLINE;

ABDOMINAL PAIN; ADULT; ALBUMINURIA; ARTICLE; ASCITES; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; FLU LIKE SYNDROME; HEADACHE; HEMATURIA; HUMAN; HUMAN TISSUE; LEG EDEMA; LIVER CIRRHOSIS; MALE; NAUSEA; SINGLE DRUG DOSE; VOMITING;

ADULT; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MINOCYCLINE; SEVERITY OF ILLNESS INDEX;

EID: 78650811738     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010363477     Document Type: Article

References (20)

1. Harms JM, Bartels H., Schlunzen F., Yonath A. Antibiotics action on the translational machinery. J Cell Sci. 2003 ; 11: 1391-1393.
2. Chopra I., Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001 ; 65: 232-260.
3. Chopra I. New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors. Drug Resist Updat. 2002 ; 5: 119-125.
4. Someya Y., Yamaguchi A., Sawai T. A novel glycylcycline, 9-(N,N-dimethylglycylamido)-6-demethyl-6-deoxytetracycline, is neither transported nor recognized by the transposon Tn10-encoded metal-tetracycline/H+ antiporter. Antimicrob Agents Chemother. 1995 ; 39: 247-249.
5. Rasmussen BA, Gluzman Y., Tally RP Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines. Antimicrob Agents Chemother. 1994 ; 38: 1658-1660.
6. Bradford PA, Weaver-Sands DT, Petersen PJ In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clinical Infectious Disease. 2005 ; 41: S315 - S332.
7. Tygacil [package insert]. Philadelphia, Pa: Wyeth Pharmaceuticals ; 2009.
8. Rello J. Pharmacokinetics, pharmacodynamics, safety, and tolerability of tigecycline. J Chemother. 2005 ; 17: S12.22.
9. Van Wart SA, Owen JS, Ludwig EA, et al. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections. Antimicrob Agent Chemother. 2006 ; 50: 3701-3707.
10. Hoffmann M., DeMaio W., Jordan RA, et al. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metabol Dispos. 2007 ; 35: 1543-1553.
11. Takikawa H. Hepatobiliary transport of bile acids and organic anions. J Hepatobiliary Pancreat Surg. 2002 ; 9: 443-447.
12. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973 ; 60: 646-659.
13. US Department of Health and Human Services, FDA, CDER, CBER, Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. 2003. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ ucm064982.htm. Accessed June 14, 2009.
14. Emea, Chmp, Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. 2005. http://www.emea.europa.eu/htms/human/humanguidelines/efficacy.htm. Accessed June 14, 2009.
15. Kalbag J., Yeh CM, Milosavljev S., et al. No influence of moderate hepatic impairment on the pharmacokinetics of lumiacoxib, an oral COX-2 selective inhibitor. Pharm Res. 2004 ; 50: 181-186.
16. Agwuh K., MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Agent Chemother. 2006 ; 58: 256-265.
17. Wu C-Y., Benet LZ Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutical drug disposition classification system (BDDCS). Pharm Res. 2005 ; 22: 11-23.
18. Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K-i, et al. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanism of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur J Pharm Science. 2006 ; 27: 447-486.
19. Benet L., Hoener B-A. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002 ; 71: 115-121. 20. Labaume J-P. Handbook of Pharmacokinetics: Toxicity Assessment of Chemicals. Chichester, UK: Ellis Horwood ; 1989.
20. Rubino CM, Forrest A., Bhavnani S., Korth-Bradley JM, Ambrose PG Toxicodynamic analyses of tigecycline in patients with hospital associated pneumonia (HAP) or community acquired pneumonia (CAP) Paper presented at: 47th ICAAC Program and Abstracts; 2007 ; American Society of Microbiology, Chicago, Ill.